In her first public speech as NCI director, Monica Bertagnolli said that under her stewardship NCI would modernize clinical trials and double patient accrual.
Cancer death rates continued to decline among men, women, children, and adolescents and young adults in every major racial and ethnic group in the U.S. from 2015 to 2019, according to the latest Annual Report to the Nation on the Status of Cancer.
Selina M. Luger, a hematologist-oncologist and acute leukemia and myeloid disorders researcher, was appointed chair of the ECOG-ACRIN Cancer Research Group Leukemia Committee.
The James P. Allison Institute at MD Anderson Cancer Center established an internal advisory council to provide scientific input and to align the work of the institute with the broader MD Anderson research enterprise.
Fox Chase Cancer Center and Weill Cornell Medicine were selected to develop a new Cancer Prevention-Interception Targeted Agent Discovery Program.
Candel Therapeutics Inc., a clinical-stage biopharmaceutical company developing viral immunotherapies, formed a collaboration with the University of Pennsylvania to study the impact of novel viral immunotherapies based on Candel’s proprietary enLIGHTEN Discovery Platform to strengthen the effects of Penn’s CAR-T cell therapies in solid tumor models.
The Max Foundation, the ABC Global Alliance, the American Society of Clinical Pathology, Cepheid, and Novartis AG are joining and committing resources to improve outcomes for people living with HR+/HER2- advanced breast care in low- and middle-income countries.
Researchers at UT Southwestern reported in the journal Nature Cancer that Talzenna (talazoparib) successfully shrank the tumors of breast cancer patients with mutations in the PALB2 gene.
In a large analysis of prostate cancer patients treated internationally across 12 randomized trials, research from UCLA Jonsson Comprehensive Cancer Center suggests that it is almost universally optimal for men to receive androgen deprivation therapy during and after radiation therapy, rather than before and during RT.
Researchers from MD Anderson Cancer Center demonstrated that adding metastasis-directed radiation therapy to intermittent hormone therapy improved progression-free survival in patients with oligometastatic prostate cancer. Findings from the multicenter EXTEND trial were presented Oct. 25 at the 2022 American Society for Radiation Oncology Annual Meeting.
